News

Nomad Foods 2025 Earnings Forecast: A Closer Look

Nomad Foods 2025 Earnings Forecast: A Closer Look

Nomad Foods 2025 Earnings Forecast Overview

Nomad Foods (NYSE: NOMD) has recently unveiled its financial forecast for the year 2025. This projection has sparked conversations in the financial community as the anticipated adjusted earnings per share (EPS) appear to fall short of the expectations set by analysts.

Adjusted Earnings Per Share Expectations

In its forecast, Nomad Foods estimates an adjusted EPS ranging from EU1.81 to EU1.85. However, this range does not meet the average forecast of EU1.89, as projected by the Bloomberg Consensus.

Market Reaction to Financial Forecast

The company experienced a decline in share value, with a substantial drop of approximately 1.5% observed during premarket trading on Tuesday. This reaction underscores the market's sensitivity to earnings forecasts and performance metrics.

Revenue and EBITDA Growth Predictions

Beyond the adjusted EPS, Nomad Foods has shared guidance on its organic net revenue and adjusted EBITDA. The company anticipates a modest growth in organic net revenue of about 1% to 3%. Additionally, they project an increase in adjusted EBITDA ranging from 2% to 4%, indicating a cautious yet optimistic approach to its financial health.

Upcoming Company Presentation

This financial outlook comes on the heels of Nomad Foods' planned presentation at the 27th Annual ICR Conference. Management is enthusiastic about the company’s ability to sustain positive economic momentum as it moves into 2025.

Confidence in 2024 Guidance

Management at Nomad Foods has also conveyed a strong level of confidence in meeting its guidance for the full year 2024. This optimism is vital for maintaining investor trust and interest in the company’s ongoing operations and strategic direction.

Looking Ahead for Nomad Foods

As Nomad Foods navigates the challenges posed by economic fluctuations and changing consumer behaviors, its 2025 earnings forecast and guiding principles play a crucial role in shaping investor perceptions and company performance.

Frequently Asked Questions

What is the 2025 earnings forecast for Nomad Foods?

Nomad Foods forecasts an adjusted EPS of EU1.81 to EU1.85, which is below the analyst consensus of EU1.89.

How did the market react to the earnings forecast?

The shares of Nomad Foods dropped approximately 1.5% in premarket trading following the earnings forecast announcement.

What are the revenue growth predictions for Nomad Foods?

Nomad Foods expects a growth in organic net revenue of 1% to 3% for 2025.

When will Nomad Foods present its financial outlook?

The company is scheduled to present its financial outlook at the upcoming 27th Annual ICR Conference.

What is the adjusted EBITDA growth expectation for 2025?

Nomad Foods anticipates an increase in adjusted EBITDA between 2% to 4% for 2025.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 311

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 138

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 58

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 357

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 559

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Assessing TJX Companies Inc: Market Sentiment and Performance

Updated Category News Views 199

Understanding TJX Companies Inc's Market Dynamics TJX Companies Inc (NYSE: TJX) is currently navigating an intriguing landscape in the stock market, characterized by an increase in short interest. Notably, the short interest as a percentage of float has surged by 6.82% since the latest report, with approximately 15.68 million shares now sold short. This accounts for 1.41%...

Continue Reading
Refresco Teamsters Achieve Historic Contractual Victory

Updated Category News Views 337

Historic Contract Ratified by Teamsters Local 767 Members of Teamsters Local 767 have made headlines with their recent contract ratification that promises significant improvements for the workers of Refresco. An overwhelming majority of 93 percent voted in favor of this new agreement, showcasing the unity and commitment of the union members. Support for Employees The...

Continue Reading
MAP Medical and Metrix-Secure Team Up for Enhanced Healthcare

Updated Category News Views 133

MAP Medical Partners with Metrix-Secure for Enhanced Services MAP Medical has officially partnered with Metrix-Secure, a recognized leader in the medical supply industry. This collaboration empowers MAP Medical to serve as an authorized distributor, providing quality medical supply solutions to a wide array of healthcare facilities. Enhancing Patient Care with Reliable...

Continue Reading
Investors Show Interest in Unusual Options for Marriott

Updated Category News Views 153

Insights into Unusual Options Activity for Marriott International Recently, there has been a notable surge in bearish sentiment among investors concerning Marriott International (NASDAQ: MAR). This shift in attitude is essential for retail traders to understand as it may indicate changes in the market landscape. These trading patterns were identified through a publicly...

Continue Reading
Caribou Biosciences Investors Have Legal Avenues Available

Updated Category News Views 135

Opportunity for Investors of Caribou Biosciences For those who invested in Caribou Biosciences, Inc. (NASDAQ: CRBU), an exciting opportunity has emerged concerning potential legal claims. The Rosen Law Firm, recognized for its dedication to investor rights, is actively reminding purchasers of Caribou securities of their rights. If you bought securities between July 14,...

Continue Reading